Compare ResMed Inc. (RMD) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Vanguard Total International Stock Index Fund ETF — how do they compare? ResMed Inc. trades at $230.12 (market cap $31.89B), while Vanguard Total International Stock Index Fund ETF trades at $84.96 (market cap $665.70B). The key difference: Vanguard Total International Stock Index Fund ETF is far larger — about 20.9× ResMed Inc.'s market cap, and ResMed Inc. pays a 1.16% dividend while Vanguard Total International Stock Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Vanguard Total International Stock Index Fund ETF for 55 Days on average.
| RMD | VXUS | |
|---|---|---|
Market Cap | $31.89B | $665.70B |
Volume | 618,314 | 4,864,744 |
Sector | Health | Sector/Thematic |
52-Week High | $277.88 | $88.41 |
52-Week Low | $182.82 | $72.17 |
Typical Hold Time | 51 Days | 55 Days |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
VXUS trades at $84.67, down 0.13% with a bearish technical signal from moving averages and oscillators. The ETF provides diversified international stock exposure excluding U.S. markets, with recent institutional buying interest from firms like QRG Capital and Baird Financial. Support levels cluster around $83-84 while resistance sits at $85.
The outlook remains cautious given technical bearishness, though long-term diversification benefits and institutional accumulation provide support. Key risks include foreign market volatility and currency fluctuations, while the absence of U.S. exposure offers portfolio hedging advantages during domestic downturns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
